Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)

Written by Emily J. Thompson, Senior Investment Analyst

ATXI%

Updated: Nov 14 2024

0mins

Financial Overview: As of September 30, cash and cash equivalents decreased to $2.6M from $4.9M at June 30, but increased by $0.8M year-to-date compared to December 31, 2023.
Pipeline Progress: Avenue's CEO, Dr. Alexandra MacLean, highlighted advancements in their treatment pipeline for neurologic diseases, particularly the potential of AJ201 for Kennedy's Disease, with topline clinical data expected soon.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Realty Income (O): Reliable Dividend Stock with 5.4% Yield

Nvidia (NVDA) Launches Vera Rubin Chip Production Six Months Early, Forecasts 155% Sales Growth

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch